A small peptide derived from corn silk called FK2 was found to reduce kidney fibrosis in mice by directly binding to IKKβ and simultaneously blocking both inflammatory and scarring pathways.
Dual pathway suppressionFK2 simultaneously blocks both the NF-κB inflammatory pathway and the TGF-β1/Smad2/3 fibrotic pathway by targeting a single enzyme, IKKβ
What the researchers found
FK2, a 9-amino-acid peptide derived from the silk of corn (Zea mays L.), was shown to inhibit renal fibrosis both in living mice and in cell cultures. The researchers identified IKKβ as the direct molecular target of FK2. By binding to IKKβ, FK2 simultaneously blocks two major signaling pathways — IKKβ/NF-κB (which drives inflammation) and TGF-β1/Smad2/3 (which drives tissue scarring).
This dual suppression reduced the inflammatory response and inhibited two key processes that contribute to kidney scarring: macrophage-to-myofibroblast transition (MMT), where immune cells transform into scar-producing cells, and epithelial-mesenchymal transition (EMT), where kidney lining cells lose their normal identity and become fibrotic.
Why it matters
Chronic kidney disease affects hundreds of millions of people worldwide, and renal fibrosis — the progressive scarring of kidney tissue — is the final common pathway that leads to kidney failure. Currently, there are no effective treatments that directly halt or reverse kidney fibrosis. FK2 is notable because it targets IKKβ to simultaneously suppress both inflammation and fibrotic cell transitions, addressing two intertwined drivers of the disease with a single molecule. As a naturally derived peptide, it also represents a promising starting point for developing new anti-fibrotic drugs.
The numbers in context
9-amino-acid peptide · derived from corn silk (Zea mays L.) · targets IKKβ directly · suppresses NF-κB and TGF-β1/Smad2/3 pathways · inhibits MMT and EMT
How the study worked
The researchers used a combination of in vivo (mouse model) and in vitro (cell culture) experiments. They tested FK2 in C57BL mice with induced kidney fibrosis and in RAW 264.7 macrophage cell lines. Molecular target identification confirmed IKKβ as a direct binding partner of FK2. Pathway analysis examined the IKKβ/NF-κB and TGF-β1/Smad2/3 signaling axes to establish the mechanism of action.
Who was studied
C57BL/6 mice with induced renal fibrosis and RAW 264.7 macrophage cell lines
What this study cannot tell us
This study was conducted in mice and cell cultures, not in humans, so it remains unknown whether FK2 would be safe and effective in people. The abstract does not report specific dosing, pharmacokinetics, or long-term safety data. The mouse model of induced kidney fibrosis may not fully replicate the complexity of chronic kidney disease in humans.
How to read the evidence
This study is graded as preliminary because it was conducted entirely in mice and cell cultures. While the results are promising and the mechanism is well-characterized, no human data exists yet to confirm safety or efficacy.
When this study was published
Published in 2026, this is a very recent study representing the current frontier of peptide-based anti-fibrotic research.
The bigger picture
Kidney fibrosis remains one of the biggest unmet needs in nephrology — once scarring takes hold, there is no approved drug to reverse it. This study adds to growing interest in bioactive peptides from natural sources as potential therapeutics. The identification of IKKβ as a druggable target that connects inflammation to fibrotic remodeling could inform broader drug development strategies beyond peptides. If FK2 or derivatives prove viable in human studies, it could represent a new class of anti-fibrotic therapy for chronic kidney disease.
Questions still open
- Will FK2 show the same anti-fibrotic effects in human kidney cells and clinical trials?
- What is the optimal dose, route of administration, and pharmacokinetic profile of FK2 for potential therapeutic use?
- Could FK2 or similar IKKβ-targeting peptides be effective against fibrosis in other organs, such as the liver or lungs?
Common questions
What is FK2 and where does it come from?
How does FK2 stop kidney scarring?
Read the original research
Peptide FK2 attenuates inflammation and pro-fibrotic cellular transitions via targeting the IKKβ/NF-κB/TGF-β1 axis in renal fibrosis.
European journal of pharmacology, 1015, 178567
Citation
Yang, Runling; Feng, Xiaocui; Zhang, Jianfeng; Chen, Tianyi; Wang, Wenqian; Liu, Yangrui; Chen, Wanru; Bai, Jingya; Zhang, Bangzhi. (2026). Peptide FK2 attenuates inflammation and pro-fibrotic cellular transitions via targeting the IKKβ/NF-κB/TGF-β1 axis in renal fibrosis.. European journal of pharmacology, 1015, 178567. https://doi.org/10.1016/j.ejphar.2026.178567